Publications by authors named "Boniface Kinvi"
Uganda started implementing mass drug administration against schistosomiasis in 2003, with district used as an implementation unit. This resulted into misclassification of communities into wrong risk levels, under-or-over treatment and over request of praziquantel (PZQ) drugs. The objective of the current study was to reviewing the community data available at World Health Organization/ESPEN database to understand the status of schistosomiasis and identify pockets with infection.
View Article and Find Full Text PDFBackground: Over the past two decades, preventive chemotherapy (PC) with praziquantel (PZQ) is the major strategy for controlling schistosomiasis in Senegal. The objective of this analysis was to update the endemicity of schistosomiasis at community level for better targeting mass treatment with PZQ in Senegal.
Methods: Demographic and epidemiological data from 1610 community health areas were analyzed using the schistosomiasis community data analysis tool of Expanded Special Project for Elimination of Neglected Tropical Diseases which developed by World Health Organization/Africa Office (WHO/AFRO).
Article Synopsis
- A study aimed at assessing progress towards eliminating soil-transmitted helminths (STHs) in sub-Saharan Africa found a significant decline in prevalence among children from 44% in 2000 to 13% in 2018, attributed to effective control programs and improved sanitation.
- Despite this progress, around 25% of implementation areas still exceeded the target threshold of 2% prevalence, with Nigeria and eight other countries accounting for the majority of these high-risk areas.
- The findings emphasize the need for ongoing investment in STH treatment and prevention to meet elimination goals by 2030, while also highlighting gaps in data and areas needing targeted interventions.
Background: Lymphatic filariasis (LF) is a vector-borne parasitic disease that is being targeted for elimination through mass drug administration (MDA). The co-distribution of in Central Africa poses a significant barrier to the expansion of the MDA due to risk of severe adverse events (SAEs) associated with the drug ivermectin that is routinely used. National LF programmes are yet to significantly scale up in co-endemic areas and need a practical approach to make preliminary decisions based on the mapping status and potential treatment strategies.
View Article and Find Full Text PDF